Welcome to our dedicated page for Myriad Genetics SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Myriad Genetics, Inc. (NASDAQ: MYGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a molecular diagnostic testing and precision medicine company, Myriad Genetics uses these filings to report financial results, material agreements, leadership changes, and other significant events.
Investors can review Form 8-K filings that announce quarterly financial results, furnish earnings press releases, and describe items such as new credit agreements or changes in executive officers. For example, recent 8-K filings have covered results for quarters ended in 2025, entry into a term loan credit facility, and the appointment or departure of senior finance executives. An 8-K/A amendment has also been used to correct a clerical error in previously furnished financial information.
In addition to current reports, Myriad Genetics files annual reports on Form 10-K and quarterly reports on Form 10-Q, which include audited or reviewed financial statements, risk factor discussions, and segment information for areas such as hereditary cancer testing, tumor profiling, prenatal testing, and pharmacogenomics. Proxy statements and other governance-related documents provide further detail on board structure and executive compensation.
On Stock Titan, these filings are updated as they become available from the SEC’s EDGAR system. AI-powered tools summarize key points, highlight important sections, and help explain complex topics such as non-GAAP financial measures, credit facility covenants, and the implications of executive transitions. Users can also focus on insider and executive-related disclosures within Forms 3, 4, and 5 when those are filed, to better understand equity awards and ownership changes.
This page is intended as a convenient starting point for reviewing Myriad Genetics’ regulatory history and understanding how the company reports its financial condition, strategic agreements, and corporate governance matters over time.